Technological advancements promote industry growth.
The field of in vitro diagnostics (IVD) continues to experience significant growth, driven by advancements in diagnostic technologies that improve accuracy, portability, and affordability. In May 2025, the U.S. Food and Drug Administration (FDA) approved the first blood test to assist in the diagnosis of Alzheimer's disease, marking a groundbreaking achievement. The "LUMIPULSE G pTau217/β-Amyloid 1-42 Plasma Ratio Test," developed by Fujirebio Diagnostics, offers a less invasive and more accessible alternative to traditional diagnostic methods such as PET scans and spinal taps by measuring specific biomarkers associated with Alzheimer's disease. This approval is expected to enhance early detection and management of Alzheimer's disease, particularly benefiting the elderly population. 【Contents】 ■ Market Overview ■ Impact of U.S. Trade Tariffs ■ Market Analysis (by Product, by Test, by Application, by End User) ■ Regional Market Analysis ■ Company Profiles
Inquire About This Product
basic information
Publisher: Visiongain Publication Month: June 2025 Report Language: English *For more details, please visit our website or refer to the sample materials.
Price range
P4
Delivery Time
P2
Applications/Examples of results
The research report provides data that serves as the basis for corporate strategies and decision-making. You can check the delivery image from the sample. We can also introduce reports from our offerings that are close to your preferences. Please feel free to contact us for any inquiries or consultations.
Company information
Data Resource Co., Ltd. provides valuable information and analytical data for business strategy planning, including the latest market information on telecommunications, computers, electronics, energy, and automotive-related sectors worldwide, as well as competitor strategies, the development of new technologies and services, regulations, and intellectual property.